Matrix metalloproteinase-1 contribution to sarcoma cell invasion

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1331-1341

  Garamszegi, Nandor ^a,b,d   Garamszegi, Susanna P ^c   Scully, Sean P ^a,c  

^a UNIVERSITY OF MIAMI   (United States)

^b NAG Biosystems   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Directional delivery; Invasion; Lamellipodia; Matrix metalloproteinase 1; Prenylation; Sarcoma

Indexed keywords

METAMORPHA;

EID: 84861558067     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01402.x     Document Type: Article

References (63)

1. Jiang X, Dutton CM, Qi WN, et al. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol. 2005; 202: 723-30.
2. Pei D. Matrix metalloproteinases target protease-activated receptors on the tumour cell surface. Cancer Cell. 2005; 7: 207-8.
3. Polette M, Clavel C, Cockett M, et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metast. 1993; 13: 31-7.
4. Pritchard SC, Nicolson MC, Lloret C, et al. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep. 2001; 8: 421-4.
5. Vachani A, Nebozhyn M, Singhal S, et al. A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma. Clin Cancer Res. 2007; 13: 2905-15.
6. Chen WT, Wang JY. Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann N Y Acad Sci. 1999; 878: 361-71.
7. Zaman MH, Matsudaira P, Lauffenburger DA. Understanding effects of matrix protease and matrix organization on directional persistence and translational speed in three-dimensional cell migration. Ann Biomed Eng. 2007; 35: 91-100.
8. Zaman MH, Trapani LM, Sieminski AL, et al. Migration of tumour cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. [erratum appears in Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13897]. Proc Natl Acad Sci U S A. 2006; 103: 10889-94.
9. Jiang X, Dutton CM, Qi W, et al. Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J Orthop Res. 2003; 21: 1063-70.
10. Yuan J, Dutton CM, Scully SP. RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res. 2005; 23: 1467-74.
11. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295: 2387-92.
12. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2: 657-72.
13. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005; 5: 203-20.
14. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metast Rev. 2006; 25: 115-36.
15. Friedl P. Dynamic imaging of cancer invasion and metastasis: principles and preclinical applications. Clin Exp Metast. 2009; 26: 269-71.
16. Friedl P, Wolf K. Proteolytic interstitial cell migration: a five-step process. Cancer Metast Rev. 2009; 28: 129-35.
17. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3: 362-74.
18. Wolf K, Friedl P. Functional imaging of pericellular proteolysis in cancer cell invasion. Biochimie. 2005; 87: 315-20.
19. Wolf K, Friedl P. Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metast. 2009, 26: 289-98.
20. Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007; 9: 893-904.
21. Magee AI, Seabra MC. Are prenyl groups on proteins sticky fingers or greasy handles?Biochem J. 2003; 376: e3-4.
22. Bergo MO, Leung GK, Ambroziak P, et al. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem. 2001; 276: 5841-5.
23. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem. 1996; 271: 5289-92.
24. Seabra MC, Reiss Y, Casey PJ, et al. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell. 1991; 65: 429-34.
25. Mor A, Philips MR. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol. 2006; 24: 771-800.
26. Caraglia M, Santini D, Marra M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer. 2006; 13: 7-26.
27. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007; 6: 541-55.
28. Konstantinopoulos PA, Papavassiliou AG. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol Sci. 2007; 28: 6-13.
29. Yuasa T, Kimura S, Ashihara E, et al. Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem. 2007; 14: 2126-35.
30. Bialek-Wyrzykowska U, Bauer BE, Wagner W, et al. Low levels of Ypt protein prenylation cause vesicle polarization defects and thermosensitive growth that can be suppressed by genes involved in cell wall maintenance. Mol Microbiol. 2000; 35: 1295-311.
31. Lantry LE, Zhang Z, Crist KA, et al. Chemopreventive efficacy of promising farnesyltransferase inhibitors. Exp Lung Res. 2000; 26: 773-90.
32. Hassan M, Feyen O, Grinstein E. Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation. Cell Oncol. 2009; 31: 437-56.
33. Clark MK, Scott SA, Wojtkowiak J, et al. Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. J Med Chem. 2007; 50: 3274-82.
34. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004; 45: 2187-95.
35. Sebti SM, Hamilton AD. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development. Expert Opin Investig Drugs. 1997; 6: 1711-4.
36. Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem. 2008; 15: 1478-92.
37. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer. 2005; 5: 405-12.
38. Abeles AM, Marjanovic N, Park J, et al. Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitors. [erratum appears in Arthritis Rheum. 2007 Oct;56(10):3510 Note: Al-Mussawir, Hayfez [corrected to Al-Mussawir, Hayf E]]. Arthritis Rheumat. 2007; 56: 2840-53.
39. Cole SL, Grudzien A, Manhart IO, et al. Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem. 2005; 280: 18755-70.
40. Michaelson D, Ahearn I, Bergo M, et al. Membrane trafficking of heterotrimeric G proteins via the endoplasmic reticulum and Golgi. Mol Biol Cell. 2002; 13: 3294-302.
41. Modiano N, Lu YE, Cresswell P. Golgi targeting of human guanylate-binding protein-1 requires nucleotide binding, isoprenylation, and an IFN-gamma-inducible cofactor. Proc Natl Acad Sci U S A. 2005; 102: 8680-5.
42. Stickney JT, Booden MA, Buss JE. Targeting proteins to membranes, using signal sequences for lipid modifications. Methods Enzymol. 2001; 332: 64-77.
43. Alexander NR, Branch KM, Parekh A, et al. Extracellular matrix rigidity promotes invadopodia activity. Curr Biol. 2008; 18: 1295-9.
44. Clark ES, Weaver AM. A new role for contacting in invadopodia: regulation of protease secretion. Eur J Cell Biol. 2008; 87: 581-90.
45. Clark ES, Whigham AS, Yarbrough WG, et al. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007; 67: 4227-35.
46. Guida WC, Hamilton AD, Crotty JW, et al. Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling. J Comp-Aided Molec Design. 2005; 19: 871-85.
47. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumour invasion. Cancer Lett. 2003; 194: 1-11.
48. Yan SJ, Blomme EA. In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections. Vet Pathol. 2003; 40: 227-36.
49. McGeehan GM, Bickett DM, Green M, et al. Characterization of the peptide substrate specificities of interstitial collagenase and 92-kDa gelatinase. Implications for substrate optimization. J Biol Chem. 1994; 269: 32814-20.
50. Yuan J, Dutton CM, Scully SP. RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res. 2005; 23: 1467-74.
51. Jiang X, Dutton CM, Qi WN, et al. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol. 2005; 202: 723-30.
52. Fong YC, Dutton CM, Cha SS, et al. Absence of a correlation between the presence of a single nucleotide polymorphism in the matrix metalloproteinase 1 promoter and outcome in patients of chondrosarcoma. Clin Cancer Res. 2004; 10: 7329-34.
53. Jiang X, Dutton CM, Qi W, et al. Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J Orthop Res. 2003; 21: 1063-70.
54. Scully SP, Berend KR, Toth A, et al. Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. Clin Orthop Relat Res. 2000: 291-303.
55. Scully SP, Berend KR, Qi WN, et al. Collagenase specificity in chondrosarcoma metastasis. Braz J Med Biol Res. 1999; 32: 885-9.
56. Berend KR, Toth AP, Harrelson JM, et al. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. J Bone Joint Surg Am. 1998; 80: 11-7.
57. Kim IY, Jeong SJ, Kim ES, et al. Type I collagen-induced pro-MMP-2 activation is differentially regulated by H-Ras and N-Ras in human breast epithelial cells. J Biochem Mol Biol. 2007; 40: 825-31.
58. Lee KW, Kim MS, Kang NJ, et al. H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells. Int J Cancer. 2006; 119: 1767-75.
59. Sun J, Qian Y, Hamilton AD, et al. Ras CAAX peptidomimetic FTI 276 selectively blocks tumour growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 1995; 55: 4243-7.
60. Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem. 1995; 270: 26802-6.
61. Kang S, Kim ES, Moon A. Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009; 21: 1317-22.
62. Lantry LE, Zhang Z, Yao R, et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 2000; 21: 113-6.
63. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?Blood. 2000; 96: 1655-69.